Skip to content

Stacey B. Armstrong

10 papers in the library · 65 citations · publishing 2023-2026

Papers

Sort Most recent Most cited

The Abuse Liability of Classic Psychedelics: A Methodological Critique and Assessment of the Quality of Evidence of Recent Studies

Current Addiction Reports August 18, 2026 Michael J. Broman, Jhuma N. Acharya, Kaltum Ahmed et al.

Abstract Purpose of Review We highlight key findings and methodological issues from recent research on the abuse liability of classic psychedelics, utilizing a GRADE to assess the quality of the evidence. Recent Findings Studies using various designs suggest that classic psychedelics (e.g., psilocybin, LSD) have low abuse potential and less dependence liability than other drugs. However, public...

Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial.

Communications medicine July 30, 2026 Stacey B Armstrong, Adam W Levin, Nathan D Sepeda et al.

Psilocybin-assisted therapy (PAT) shows promise for treating PTSD in adults but hasn't been studied in U.S. military Veterans, who face higher symptom severity and suicide risk. This open-label pilot trial evaluated the safety and feasibility of PAT in Veterans with severe, treatment-resistant PTSD. The clinical trial was pre-registered at ClinicalTrials.gov (NCT05554094). The eligibility...

Development and assessment of a psychedelic-assisted therapy music playlist for clinical trials: Theory, intentionality, and metrics

Journal of Psychedelic Studies May 28, 2026 Rafaelle Lancelotta, Paul Nagib, Stacey B. Armstrong et al.

Abstract Background and Purpose Music plays a central role in psychedelic-assisted therapy, yet few methodologies exist to create and assess therapeutic playlists. This study aimed to illustrate a methodology for developing and evaluating a music playlist for a clinical psilocybin trial using an integrative framework grounded in theory, intentionality, and metrics. Methods A playlist was...

Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder

Journal of Psychedelic Studies September 4, 2025 Alan K. Davis, Meghan DellaCrosse, Nathan D. Sepeda et al. 4 citations

Abstract Background Major Depressive Disorder (MDD) is a leading cause of disability and economic loss, with high recurrence and treatment resistance. Psilocybin-assisted therapy (PAT) shows promise in reducing depressive symptoms, but long-term effects are unknown. We aimed to determine the long-term safety and efficacy of PAT for MDD over a five-year follow-up period. Methods Individuals who...

Social Workers' Attitudes and Beliefs about MDMA-Assisted Therapy for Adolescents with PTSD.

Social Work April 1, 2025 Maha N. Mian, Jordan Horan, Taweh Hunter et al. 1 citation

Given the widespread interest and ongoing study on MDMA-assisted therapy (MDMA-AT) for PTSD, its implications for unique populations-such as adolescents-require further understanding. Social workers will likely play a crucial role in the potential implementation of this intervention, but their perspectives remain unknown. The study includes 222 social workers randomized to read one of two...

Psychedelic research at a crossroads

Science September 19, 2024 Stacey B. Armstrong, Alan K. Davis 6 citations

There is an urgent need to develop better treatments for mental health conditions that affect one in every eight people in the world. To combat this concern, psychedelic drugs have been combined with psychotherapy and studied in clinical trials in the United States and Europe. Psychedelics are hallucinogenic drugs that alter brain activity and facilitate altered states of consciousness. The...

The Epidemiology of Psychedelic Use Among United States Military Veterans

Journal of Psychoactive Drugs September 12, 2024 Katinka Hooyer, Rachel Yehuda, Alan K. Davis et al. 4 citations

We sought to identify patterns of psychedelic use among United States military veterans, compare demographic variables and perspectives of those who did and did not report use, and characterize benefits and adverse outcomes associated with use. Respondents (N = 426) were recruited to complete an online cross-sectional survey. Approximately one-half (51%) reported using psychedelics. Most did so...

Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans.

Military psychology : the official journal of the Division of Military Psychology, American Psychological Association 2024 Stacey B. Armstrong, Yitong Xin, Nathan D. Sepeda et al. 19 citations

This study evaluated prospective associations of ibogaine and 5-MeO-DMT treatment for risky alcohol use and post-traumatic stress disorder (PTSD) symptoms among United States (US) Special Operations Forces Veterans (SOFV). Data were collected during standard clinical operations at pre-treatment and 1-month (1 m), 3-months (3 m), and 6-months (6 m) post-treatment in an ibogaine and 5-MeO-DMT...

Differences in attitudes and beliefs about psychedelic-assisted therapy among social workers, psychiatrists, and psychologists in the United States

Journal of Psychedelic Studies August 21, 2023 Stacey B. Armstrong, Adam W. Levin, Yitong Xin et al. 12 citations

Abstract Background and aims Because psychedelic-assisted therapy (PAT) is likely to be provided by interdisciplinary professional teams comprised of social workers, psychologists, and psychiatrists, understanding the acceptability of this treatment approach among these professional disciplines is essential as the treatment advances through approval processes at the Food and Drug...

Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD

BMJ Open May 1, 2023 Alan K. Davis, Adam W. Levin, Paul Nagib et al. 19 citations

Introduction Psilocybin-assisted therapy has shown significant promise in treating the cluster of mood and anxiety symptoms that comprise post-traumatic stress disorder (PTSD) but has yet to be tested specifically in this condition. Furthermore, current pharmacological and psychotherapeutic treatments for PTSD are difficult to tolerate and limited in efficacy, especially in the US Military...